Addressing the global crisis of depression

In a world grappling with many health care challenges, from infectious diseases to chronic problems like heart disease and diabetes, it is easy to overlook a condition is often hidden by those who are suffering. Shockingly, depression is the leading cause of disability worldwide.  It is estimated that one-in-four people of working age either are or have suffered from depression. The personal cost can be great; even tragic. The economic cost for societies the world over could be staggering, and that burden is on the rise. 

On November 25, policymakers, healthcare providers, researchers, employers and patient groups will gather in London to consider national strategies to tackle what has become a leading cause of illness globally. Depression is a brain disease that severely impacts patients’ lives. Roughly half of patients fail to respond to initial anti-depressant therapy for reasons that include lack of efficacy, poor tolerability or residual symptoms such as cognitive dysfunction. No one understands this better than Lundbeck, the leading research-based pharmaceutical company dedicated to diseases of the brain, which is why CEO Ulf Wiinberg will join the panel discussion about treatment options in the 21st Century that day in London. Also sharing their views will be health ministers from the UK and Denmark, and experts from Sweden, Canada, Germany, the UK and the European Brain Council. 

While the rate of diagnosis for depression continues to rise, nearly half of those suffering in the workforce are going untreated. On November 25, join the conversation and learn what some of the leading minds on the subject believe can be done about one of the world’s great health care challenges. Follow #DepressionSummit on Twitter or visit for more information.